Calidi Biotherapeutics (CLDI) Non-Current Assets (2021 - 2026)
Calidi Biotherapeutics (CLDI) posted quarterly Non-Current Assets of $2.6 million for Q4 2025, down 34.24% year-over-year from $4.0 million in Q4 2024, and down 13.33% quarter-over-quarter from $3.0 million in Q3 2025.
Calidi Biotherapeutics (CLDI) Non-Current Assets (2021 - 2026) Analysis & Trends
Calidi Biotherapeutics' Non-Current Assets history runs 5 years deep, the most recent figure standing at $2.6 million for Q4 2025.
- In Q4 2025, Non-Current Assets fell 34.24% year-over-year to $2.6 million; the TTM figure through Dec 2025 stood at $12.5 million (down 33.15% YoY), while the FY2025 annual figure was $2.6 million, down 34.24% from the prior year.
- Non-Current Assets for Q4 2025 stood at $2.6 million, down from $3.0 million in the prior quarter.
- The five-year high for Non-Current Assets was $230.3 million in Q4 2021, with the low at -$10.4 million in Q3 2023.
- The 5-year median for Non-Current Assets is $5.5 million (2024), against an average of $52.2 million.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets sank 124.92% in 2023, then jumped 142.71% in 2024.
- Calidi Biotherapeutics' Non-Current Assets stood at $230.3 million in 2021, then tumbled by 81.57% to $42.5 million in 2022, then sank by 86.54% to $5.7 million in 2023, then sank by 30.81% to $4.0 million in 2024, then plunged by 34.24% to $2.6 million in 2025.
- Business Quant data shows CLDI's Non-Current Assets at $2.6 million in Q4 2025, $3.0 million in Q3 2025, and $3.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - | 1.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.78 Mn |
| Dec 31, 2025 | 2.60 Mn |
| Sep 30, 2025 | 3.00 Mn |
| Jun 30, 2025 | 3.30 Mn |
| Mar 31, 2025 | 3.58 Mn |
| Dec 31, 2024 | 3.96 Mn |
| Sep 30, 2024 | 4.44 Mn |
| Jun 30, 2024 | 4.81 Mn |
| Mar 31, 2024 | 5.47 Mn |
| Dec 31, 2023 | 5.72 Mn |
| Sep 30, 2023 | -10.39 Mn |
| Jun 30, 2023 | 43.21 Mn |
| Mar 31, 2023 | 42.91 Mn |
| Dec 31, 2022 | 42.45 Mn |
| Sep 30, 2022 | 41.68 Mn |
| Jun 30, 2022 | 230.26 Mn |
| Mar 31, 2022 | 230.20 Mn |
| Dec 31, 2021 | 230.29 Mn |